Microbes, Histology, Blood Analysis, Enterotoxins, and Cytokines: Findings From the ASERF Systemic Symptoms in Women–Biospecimen Analysis Study: Part 3 Print
Patricia McGuire, MD, Caroline Glicksman, MD, MSJ, Roger Wixtrom, PhD, C James Sung, MD, FCAP, Robert Hamilton, PhD, D(ABMLI), Marisa Lawrence, MD, Melinda Haws, MD, Sarah Ferenz, BA, Marshall Kadin, MD

Aesthetic Surgery Journal, sjac225

Background: There has been an increasing need to acquire rigorous scientific data to answer the concerns of physicians, patients, and the FDA regarding the self-reported illness identified as breast implant illness (BII). There are no diagnostic tests or specific laboratory values to explain the reported systemic symptoms described by these patients.

Objectives: The aim of this study was to determine if there are quantifiable laboratory findings that can be identified in blood, capsule tissue pathology, or microbes that differentiate women with systemic symptoms they attribute to their implants from 2 control groups.  

>> View on the Aesthetic Surgery Journal  Website